POMDOCTOR LIMITED (POM) Income Statement
POM 2025 at a glance
Fiscal year ended December 31, 2025 · Chinese yuanPOM revenue and net income
Where POM's revenue goes
2025Each bar shows an amount and its share of revenue. POM kept −53.2% of revenue as net income.
POM profit margins
POM growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +16.7% | +17.7% | +23.1% | −22.4% |
| Gross profit | +9.6% | −1.6% | −0.5% | −36.4% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
POM income statement in Chinese yuan
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥399.9M | CN¥342.6M | CN¥304.9M | CN¥245.2M | CN¥215.4M | CN¥141.2M | CN¥34.44B | CN¥35.98B | CN¥33.53B | CN¥31.36B |
| Cost of revenue | CN¥347.6M | CN¥294.9M | CN¥266.1M | CN¥190.4M | CN¥162.9M | CN¥87.5M | CN¥15.50B | CN¥16.67B | CN¥14.04B | CN¥12.64B |
| Gross profit | CN¥52.3M | CN¥47.7M | CN¥38.7M | CN¥54.9M | CN¥52.5M | CN¥53.7M | CN¥18.94B | CN¥19.32B | CN¥19.50B | CN¥18.72B |
| Research & development | CN¥12.9M | CN¥3.0M | CN¥3.4M | CN¥3.6M | CN¥4.3M | CN¥2.0M | — | — | — | — |
| Sales, general & admin | CN¥155.9M | CN¥68.2M | CN¥56.0M | CN¥54.9M | CN¥103.0M | CN¥292.2M | — | — | — | — |
| Total operating expenses | CN¥168.7M | CN¥73.5M | CN¥61.0M | CN¥58.5M | CN¥132.2M | CN¥294.1M | CN¥30.10B | CN¥1.12B | CN¥983.0M | CN¥10.36B |
| Operating income | −CN¥116.4M | −CN¥25.8M | −CN¥22.2M | −CN¥3.6M | −CN¥79.7M | −CN¥240.4M | CN¥4.37B | CN¥3.90B | CN¥4.26B | CN¥3.11B |
| Interest expense | CN¥12.9M | CN¥13.0M | CN¥13.8M | CN¥16.0M | CN¥16.3M | CN¥14.0M | CN¥1.59B | CN¥1.53B | CN¥1.52B | CN¥1.50B |
| Income before taxes | −CN¥130.9M | −CN¥37.4M | −CN¥36.9M | −CN¥19.8M | −CN¥96.2M | −CN¥256.5M | CN¥3.98B | CN¥2.23B | CN¥3.76B | CN¥1.99B |
| Income taxes | CN¥375 | — | — | — | — | — | CN¥1.20B | CN¥120.0M | −CN¥125.0M | CN¥761.0M |
| Net income | −CN¥212.6M | −CN¥143.4M | −CN¥145.4M | −CN¥125.5M | −CN¥188.4M | −CN¥256.4M | CN¥3.03B | CN¥398.0M | CN¥2.69B | CN¥1.13B |
| EBITDA | −CN¥117.9M | −CN¥24.3M | −CN¥23.0M | −CN¥3.8M | −CN¥58.6M | −CN¥221.5M | CN¥5.12B | CN¥8.02B | CN¥9.52B | CN¥8.97B |
| Gross margin | 13.1% | 13.9% | 12.7% | 22.4% | 24.4% | 38.0% | 55.0% | 53.7% | 58.1% | 59.7% |
| Operating margin | −29.1% | −7.5% | −7.3% | −1.5% | −37.0% | −170.3% | 12.7% | 10.8% | 12.7% | 9.9% |
| Net margin | −53.2% | −41.9% | −47.7% | −51.2% | −87.5% | −181.6% | 8.8% | 1.1% | 8.0% | 3.6% |
| Jun '26 | Mar '20 | Dec '19 | Sep '19 | Jun '19 | Mar '19 | Dec '18 | Sep '18 | Jun '18 | Mar '18 | Dec '17 | Sep '17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥27.1M | CN¥8.75B | CN¥8.34B | CN¥16.62B | CN¥7.69B | CN¥9.48B | CN¥8.81B | CN¥9.40B | CN¥8.08B | CN¥9.69B | CN¥8.38B | CN¥8.77B |
| Cost of revenue | CN¥23.4M | CN¥3.87B | CN¥3.77B | CN¥3.95B | CN¥3.23B | CN¥4.55B | CN¥4.30B | CN¥4.33B | CN¥3.31B | CN¥4.73B | CN¥3.51B | CN¥3.54B |
| Gross profit | CN¥3.7M | CN¥4.88B | CN¥4.58B | CN¥12.67B | CN¥4.46B | CN¥4.92B | CN¥4.52B | CN¥5.07B | CN¥4.76B | CN¥4.97B | CN¥4.87B | CN¥5.23B |
| Research & development | CN¥15.6M | — | — | — | — | — | — | — | — | — | — | — |
| Total operating expenses | CN¥37.8M | CN¥38.0M | CN¥7.39B | CN¥7.56B | CN¥6.88B | CN¥325.0M | CN¥282.0M | CN¥264.0M | CN¥235.0M | CN¥339.0M | CN¥267.0M | CN¥7.30B |
| Operating income | −CN¥34.1M | CN¥1.22B | CN¥962.0M | CN¥2.19B | CN¥842.0M | CN¥1.22B | CN¥709.0M | CN¥1.15B | CN¥942.0M | CN¥1.10B | CN¥1.26B | CN¥1.47B |
| Interest expense | CN¥895,705 | — | CN¥389.0M | CN¥805.0M | CN¥403.0M | CN¥397.0M | CN¥410.0M | CN¥387.0M | CN¥367.0M | CN¥365.0M | CN¥359.0M | CN¥376.0M |
| Income before taxes | −CN¥34.8M | CN¥85.0M | CN¥957.0M | CN¥1.75B | CN¥644.0M | CN¥1.28B | −CN¥31.0M | CN¥948.0M | CN¥613.0M | CN¥702.0M | CN¥1.23B | CN¥1.32B |
| Income taxes | CN¥9,823 | −CN¥294.0M | CN¥384.0M | CN¥316.0M | CN¥205.0M | CN¥310.0M | −CN¥142.0M | CN¥137.0M | CN¥66.0M | CN¥59.0M | −CN¥720.0M | CN¥452.0M |
| Net income | −CN¥33.6M | CN¥45.0M | CN¥808.0M | CN¥365.0M | CN¥494.0M | CN¥363.0M | CN¥105.0M | CN¥233.0M | CN¥178.0M | CN¥136.0M | CN¥2.21B | CN¥305.0M |
| EBITDA | −CN¥34.1M | CN¥1.13B | CN¥932.0M | CN¥4.42B | CN¥1.15B | CN¥2.53B | CN¥1.83B | CN¥2.27B | CN¥2.11B | CN¥2.06B | CN¥3.28B | CN¥2.54B |
| Gross margin | 13.7% | 55.8% | 54.9% | 76.2% | 58.1% | 52.0% | 51.3% | 53.9% | 59.0% | 51.2% | 58.1% | 59.6% |
| Operating margin | −125.9% | 13.9% | 11.5% | 13.2% | 11.0% | 12.9% | 8.0% | 12.2% | 11.7% | 11.4% | 15.0% | 16.8% |
| Net margin | −124.2% | 0.5% | 9.7% | 2.2% | 6.4% | 3.8% | 1.2% | 2.5% | 2.2% | 1.4% | 26.4% | 3.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in Chinese yuan as reported in POM's financial statements (latest annual report filed May 14, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
POM financial results
In fiscal year 2025 (ended December 31, 2025), POMDOCTOR LIMITED reported revenue of CN¥399.9 million, up 16.7% from the year before. It had a net loss of CN¥212.6 million, a net profit margin of −53.2%. Over five years revenue grew at an average rate of 23.1% a year. Figures are in Chinese yuan, the currency of its financial statements.
See the POM stock overview for the latest quote and news, or the POM chart for price history and technical indicators.
POM income statement FAQ
What is POMDOCTOR LIMITED's annual revenue?
POMDOCTOR LIMITED reported total revenue of CN¥399.9 million for fiscal year 2025, which ended on December 31, 2025. That was up 16.7% from CN¥342.6 million the previous year.
Is POMDOCTOR LIMITED profitable?
No. POMDOCTOR LIMITED reported a net loss of CN¥212.6 million in fiscal 2025, a net profit margin of −53.2%; its operating margin was −29.1%.
What is POMDOCTOR LIMITED's gross margin?
POMDOCTOR LIMITED's gross margin was 13.1% in fiscal 2025: for every $100 of revenue, POMDOCTOR LIMITED kept $13 after the direct cost of its products and services.
How much does POMDOCTOR LIMITED spend on research and development?
POMDOCTOR LIMITED spent CN¥12.9 million on research and development in fiscal 2025, 3.2% of revenue.
How fast is POMDOCTOR LIMITED growing?
Revenue grew 23.1% a year on average over the last five fiscal years, from CN¥141.2 million to CN¥399.9 million.
When does POMDOCTOR LIMITED's fiscal year end?
POMDOCTOR LIMITED's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on May 14, 2026.